Ubiquitin and Ubiquitin-Like Modifications of the p53 Family  by Watson, Ian R. & Irwin, Meredith S.
Ubiquitin and Ubiquitin-Like Modifications of the p53 Family1
Ian R. Watson*,y and Meredith S. Irwin*,z
*Cancer Research Program and Division of Hematology–Oncology, Hospital for Sick Children, University of
Toronto, 555 University Avenue, Toronto, Ontario, Canada M5G 1X8; yDepartment of Laboratory Medicine and
Pathobiology, University of Toronto, 1 King’s College Circle, Toronto, Ontario, Canada M5S 1A8; zDepartment
of Pediatrics and Institute of Medical Science, University of Toronto, 1 King’s College Circle, Toronto, Ontario,
Canada M5S 1A8
Abstract
Regulation of p53 by the ubiquitin–proteasomal path-
way has been studied considerably. Studies have also
demonstrated that the ubiquitin-like proteins SUMO-1
and NEDD8 modify p53. Similarly, p63 and p73 are
subject to regulation by ubiquitin and ubiquitin-like
modifications, and perturbations of these pathways in
the regulation of the p53 family have been implicated in
tumorigenesis and developmental abnormalities. Here,
we provide an overview of the current understanding of
the regulation of the p53 family by covalent modifica-
tion by ubiquitin, SUMO-1, and NEDD8.
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Introduction to the p53 Family
The p53 family consists of three members: p53, p63, and
p73. Since the discovery of p63 and p73 almost 10 years
ago, it has become apparent that they are not merely
redundant ‘‘p53-like’’ genes. Although there are several
similarities between the three genes and their protein prod-
ucts, there are also interesting differences, suggesting that
each protein may have a unique role in diverse processes
ranging from development to tumorigenesis. Thus, knowl-
edge of the distinct pathways that regulate the levels and
activity of each p53 family protein will likely shed light on the
functions of these proteins. The regulation of the activity and
stability of p53 by ubiquitination has been studied exten-
sively. Ubiquitin is best known as a posttranslational modi-
fication that targets proteins for degradation through the
26S proteasome; however, the role of ubiquitin has ex-
panded to involve additional functions. Along those lines,
ubiquitin-like (UBL) proteins, which consist of a family of at
least 10 members, have diverse functions that are not
necessarily associated with proteasomal degradation. p53
function is regulated by at least two UBL proteins SUMO-1
and NEDD8, and early data suggest that ubiquitin, SUMO-1,
and NEDD8 modifications modulate both p63 and p73
functions. This review will concentrate on ubiquitination,
sumoylation, and neddylation of the p53 family, with par-
ticular focus on p63 and p73.
Structure and Function of the p53 Family
p53 is a sequence-specific DNA-binding transcription factor
that plays a central role in the cellular response to oncogenic
stimuli and cytotoxic stress, such as DNA damage, by initiating
cell cycle arrest and apoptosis, predominantly through its ability
to enhance the transcription of genes that regulate these
processes (e.g., p21, PUMA, and BAX ). p63 and p73 share
significant homology in three functional protein domains. p63
and p73 proteins share approximately 25%, 60%, and 35%
amino acid identity with p53 in N-terminal transactivation (TA),
central DNA binding, and C-terminal oligomerization domains,
respectively. Certain isoforms of p63 and p73 have additional
domains not found in p53. For example, both p63a and p73aC-
terminal isoforms have a sterile a motif (SAM), which usually
functions as a protein–protein interaction motif. p63 and p73
are also able to bind canonical p53 DNA-binding sites [1,2],
transactivate 53 target genes [2,3], and induce cell cycle arrest
and apoptosis [2,4,5]. Although p63 and p73 can bind to known
p53-responsive elements in the promoter of p53 target genes,
there are clear differences in the preferred binding site sequence
for p63 [6] and likely differences in target p73-responsive ele-
ments as well. As a result, p53, p63, and p73 differentially induce
target genes. Several unique p63 and p73 target genes have
been identified, including PERP for p63 [7], Aquaporin 3 for
p73 [8], and JAG1/2 for p63/p73 [9]. Further identification of
genes that are specific targets of each p53 family protein will
likely provide insight into their unique functions.
p63 and p73 genes give rise to multiple mRNA that, when
translated, produce several different protein isoforms (Figure 1).
For more than two decades, it was believed that, in contrast to
p63 and p73, the p53 gene encoded one predominant mRNA,
resulting in a single protein. However, recent studies clearly
demonstrate the existence of multiple p53 protein isoforms as
well (reviewed in Murray-Zmijewski et al. [10]). Multiple p53,
p63, and p73 protein isoforms contain different protein domains
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as a result of alternative splicing, alternative promoter usage,
and alternative initiation of translation. The p53 gene encodes
at least two N-terminally truncated isoforms D40p53 and
D133p53, which lack the TA domain. D40p53 is generated
by alternative initiation of translation at a second ATG-40
located within exon 4 [11–13] and by alternative splicing of
intron 2 (Figure 1A), which also results in translation from the
second ATG [12]. Furthermore, there are at least four alterna-
tively spliced C-terminal p53 isoforms, which include full-
length p53 (a), p53b (formerly known as p53i9) [14,15], p53g
[14], andDp53 [16]. Interestingly, p53b and p53g isoforms lack
the oligomerization domain, and Dp53 lacks the extreme C-
terminus of the DNA-binding domain. For p73, there are at
least seven C-terminal isoforms generated either by alterna-
tive splicing (a, b, g, y, q, and ~) [3,17,18] or by alternative
termination of translation (D) [19] (Figure 1B). In addition, the
p73 gene encodes four N-terminal isoforms that include the
full-length TAp73 and the N-terminally truncated isoforms
that are collectively termed DTAp73 or DNp73 due to the fact
these isoforms lack the TA domain. TheN-terminally truncated
isoforms are generated as a result of transcription from an
alternative promoter within intron 3 (DNp73) [20], translation
from an alternative initiation site (DNVp73) [19], and alternative
N-terminal splicing (DEx2p73 and DEx2/3p73) [3]. DNVp73
isoforms are transcribed from the same promoter used to
generate the TA isoforms of p73; however, alternative N-
terminal splicing of intron 3 (exon 3V) allows for initiation of
translation within exon 3V, producing a protein indistinguish-
able from DNp73 [19]. Theoretically, p73 can be expressed as
more than 30 mRNA variants encoding for multiple proteins;
however, only 14 have been described. Lastly, p63 exists as
three alternatively spliced C-terminal isoforms (a, b, and g)
(Figure 1C) [2]. Similar to p73, p63 encodes two N-terminal
isoforms that include the full-lengthTAp63and theN-terminally
truncated DNp63 isoforms generated by transcription from
an alternative promoter within intron 3. Thus, p63 can be
expressed as six mRNA variants that encode six different
p63 proteins.
The N-terminally truncated DN isoforms of p63 and p73
lack the TA domain and, in general, have antiapoptotic
properties. Thus, although both the TA and DN isoforms of
p63 and p73 can bind p53 DNA-binding sites [1,2,20], in
Figure 1. Schematic representation of the gene structure of the p53 family. The approximate exon regions encoding the unique amino acids for DN isoforms
(orange), TA domain (TAD; red), DNA binding (DBD; blue), oligomerization (OD; yellow), and SAM domains (green) are indicated by color. Untranslated regions
are shaded black. Arrows indicate transcriptional start sites. (A) The C-terminal splicing patterns generating full-length p53a, p53, p53c, and Dp53 are shown. The
p53 isoforms that include the entire TA domain are transcribed from P1 and the recently described P1V transcription initiations sites, and D133p53 is transcribed
from the P2 promoter located within intron 4. The alternative N-terminal splicing of intron 2 is indicated. (B) The C-terminal splicing patterns generating p73a, p73,
p73c, p73d, and p73e are shown. The DNp73 isoforms are transcribed from the P2 promoter located within intron 3 (designated exon 3 V). The alternative N-terminal
splicing generating DEx2p73 and DEx2/3p73 is indicated. (C) The C-terminal splicing patterns generating p63a, p63, and p63c are shown. The DNp63 isoforms
are transcribed from the P2 promoter located within intron 3 (designated as exon 3 V). Exon size and approximate contribution of exons to the indicated functional
domains are not drawn to scale.
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general, only TA isoforms can transactivate promoters of
p53 target genes and induce apoptosis [2,4,5,21,22]. DN
isoforms act as dominant-negative inhibitors for TA iso-
forms of all three p53 family members by forming hetero-
oligomers that generate an abortive transcriptional complex
[2,19,22–24] and by competing directly for p53 DNA-binding
sites [2,20,21]. Studies have also shown that DNp73 can
enhance transformation by oncogenes such asRas [25]. The
complexity of this scenario has recently increased, given
recent data suggesting that some DN isoforms of p63 and
p73 can transactivate distinct target genes and, in certain
cases, suppress growth [26]. Furthermore, different p63 and
p73 C-terminal isoforms include significant variations in
coding sequences, resulting in functional differences in terms
of their ability to transactivate target genes and induce
apoptosis. The different isoforms are likely subject to specific
posttranslational modifications. Importantly, the variation in
p53 family protein splice forms is conserved in lower organ-
isms, includingDrosophila and zebrafish [10], suggesting that
isoform-specific functions and posttranslational regulation
are likely to be important.
Roles in Cancer and Development
Perhaps the most surprising discoveries regarding p63
and p73 functions emerged as a result of data from geneti-
cally engineered knockout mice. p63/ and p73/mice had
significant neuronal and ectodermal developmental abnor-
malities, respectively [20,27,28]. Of note, the original knock-
out mice generated for both p63 and p73 had deletions of all
TA and DN isoforms. p73/mice have significant neurologic
abnormalities due to either the absence and/or the loss of
specific populations of neurons [20]. DNp73 is the predomi-
nant isoform in the murine fetal nervous system, and loss of
this antiapoptotic p73 isoform leads to enhanced apoptosis in
cortical and sympathetic ganglia neurons. The mechanism
whereby DNp73 promotes survival is likely a combination of
inactivation of full-length proapoptotic p53 family proteins
(p53, TAp63, and TAp73) and activation of mitochondrial
pathways (reviewed in Irwin and Miller [29]). p63/ mice
have significant limb and craniofacial malformations, as well
as failure of development of the skin and other epithelial
tissues [28]. Interestingly, germline mutations in p63 have
been reported in patients with ectodermal dysplasia syn-
dromes, including ectrodactyly–ectodermal dysplasia and
facial cleft (EEC), ankyloblpharon–ectodermal dysplasia–
clefting (AEC), limb–mammary syndrome (LMS), and non-
syndromic split-hand/foot malformation (SHFM) [30]. Like
p63/ mice, patients with these clinical syndromes have
varying degrees of craniofacial (cleft lip and palate), limb,
skin, and hair abnormalities, and p63 genotype–phenotype
correlations are apparent. Certain mutations solely affect
specific isoforms (e.g., AEC patients have p63 mutations in
exon 13, which includes the SAM domain that is only present
in a isoforms). Furthermore, some of these mutations affect
amino acid residues that undergo posttranslational modifica-
tions, such as sumoylation and ubiquitination (see below).
Additional evidence for the importance of isoform-specific
expression during development includes a recent report by
Jacobs et al. [31] demonstrating that, in the developing
nervous system, only TAp63a and TAp63g isoforms are ex-
pressed. TAp63 was shown to be an essential proapoptotic
protein in neurons, both alone and in combination with p53
[31]. Taken together, these findings again support that each
isoform is likely to have specific biologic and biochemical
activities. To date, there have been no reported isoform-
specific knockout mice, but their generation is likely to reveal
important information.
The p53 family proteins also appear to have distinct roles
in tumorigenesis. Unlike p53, which is mutated in over 50% of
all human cancers and is inactivated in a further 20%, p63 and
p73 mutations are rarely observed in human cancer [32]. In
addition, p53/mice, as well as mice engineered to express
tumor-derived p53mutant proteins, develop cancers [33,34];
however, initial reports suggested that p63/ and p73/
mice were not tumor-prone. Although not mutated, accumu-
lating evidence suggests that the relative expression and
stability of the different N-terminal isoforms of p63 and p73
may contribute to a role in tumorigenesis. The full-length
TA isoforms of p63 and p73 have proapoptotic ‘‘tumor-
suppressor-like’’ properties, whereas the DN isoforms of
p63 and p73 generally have antiapoptotic ‘‘oncogene-like’’
properties. TAp73 is induced by a wide variety of chemother-
apeutic agents [35–37], and blocking TAp73 function pro-
motes survival and leads to enhanced chemoresistance
[38–40]. Further support for a role of p63 and p73 in tumor-
igenesis was provided by a recent study of heterozygous
p63+/ and p73+/ mice and compound p53/p63/p73 knock-
out mice [41]. Aged p63+/ and p73+/ mice develop spon-
taneous tumors and premalignant lesions, and loss of the
second allele of p63 and p73 was demonstrated in several of
these tumors, suggesting that at least certain isoforms of p63
and p73 are tumor-suppressor proteins. In addition, loss of
p63 or p73 cooperates with loss of p53 in tumor development
because compound p53+/;p63+/ and p53+/;p73+/ mice
develop a spectrum of tumors different from that of p53+/
mice. Finally, in comparison to p53+/ mice, mice hetero-
zygous for both p53 and p63 or p73 have both larger tumor
burdens and a higher incidence of metastatic lesions. Of
note, another p63+/ mouse generated on a different genetic
background, using an alternative gene targeting strategy,
did not develop tumors but demonstrated features of pre-
mature aging [42,43].
Recent evidence from human tumors also supports the
idea that, for many types of cancer, the relative balance
between the TA and DN isoforms may be important in tumor
development and/or progression. The ‘‘oncogenic’’ DN iso-
forms of p53 family proteins are overexpressed in a number
of human cancers. Specifically, DNp73 expression has been
shown to be elevated in breast, ovarian, hepatocellular,
prostate, colon, and neuroblastoma tumors [22,44–48]. In-
creasedDNp73 expression in several of the abovementioned
tumors has been associated with poor prognosis in patients,
and this has been attributed to the ability of DNp73 to inhibit
p53 and TAp73, resulting in decreased apoptotic response
and chemoresistance [22,45,49,50]. Furthermore, DNp63
expression is elevated in primary head and neck squamous
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cell carcinoma (HNSCC) and other squamous epithelial
malignancies such as cervical, lung, and esophageal cancers
[51–53]. Recently, DNp63a overexpression in HNSCC cells
was shown to promote the survival of these tumor cells
through inhibition of TAp73-dependent apoptosis both by
competition for promoter binding and by physical interaction
with TAp73 [40]. Lastly, Bourdon et al. [14] reported that
D133p53 mRNA, a p53 mRNA that (like the DN isoforms of
p63/p73) lacks the TAD, was detected in human breast tumor
samples but not in normal breast sample controls. Whether
D133p53 protein levels are similarly increased in tumors
has not been addressed. Conversely, loss of expression of
the full-length TAp63 and TAp73 isoforms has been reported
in many tumors, including leukemias, bladder cancers,
mammary tumors, and squamous cell carcinomas (reviewed
in Moll and Slade [32]). Taken together, the data from
mouse models and human tumors suggest that the balance
between the expression of p53, p63, and p73 and the balance
between various TA and DN isoforms likely affect the final
signaling pathway leading to apoptosis or survival. Therefore,
understanding the regulatory mechanisms, such as post-
translational modifications, that differentially modulate TA
and DN isoform activity and stability are of particular interest
because therapeutic modulation of the proapoptotic and
antiapoptotic isoforms of the p53 family has potential thera-
peutic benefits in treating human cancers.
The activity of p53 is highly regulated by posttranslational
modifications, protein–protein interactions, and protein sta-
bilization [54,55]. p53 stability is regulated through the ubiq-
uitin–proteasomal pathway by a number of E3 ubiquitin
ligases, many of which have been shown to be involved in
negative autoregulatory feedback loops with p53 [56]. In con-
trast, only a few E3 ubiquitin ligases with specificity toward
p63 and p73 have been identified. None of the known p63/
p73–specific E3 ubiquitin ligases is involved in negative
autoregulatory feedback loop mechanisms, although there
is evidence for such regulation [57–59]. There has been
almost no overlap of specificity of the known E3 ubiquitin
ligases for the different members of the p53 family; however,
many of the same posttranslational modifications, such as
phosphorylation, acetylation, and sumoylation, and their re-
spective regulators modulate the activity of multiple p53
family members. It is conceivable that differential regulation
of the p53/p63/p73 protein isoforms, perhaps by UBL mole-
cules, may account for some of the different functional
activities and stabilities for the various isoforms.
Ubiquitination of the p53 Family
Ubiquitin is an evolutionarily conserved 76-amino-acid poly-
peptide. Ubiquitin was the first example of a protein that can
modify another protein and act as a posttranslational modifi-
cation. Although ubiquitin modifications have been shown to
have multiple cellular functions, its most commonly reported
function is targeting substrate proteins for degradation
through the 26S proteasome [60,61]. The process of covalent
attachment of ubiquitin, known as ubiquitination or ubiquityla-
tion, occurs through sequential steps catalyzed by ubiquitin-
activating (E1), ubiquitin-conjugating (E2), and ubiquitin ligase
(E3) enzymes (as summarized in Figure 2). A ubiquitin
conjugation cascade is hierarchical, as eukaryotic genomes
encode a single or (at most) a few E1s, amoderate number of
E2s (approximately 60 in mammals), and a larger number of
E3s [62]. Substrates can be modified by monoubiquitins,
multiple monoubiquitins, and polyubiquitin chains that may
be linked at any of the seven lysine residues within ubiquitin
(K6-, K11-, K27-, K29-, K33-, K48-, and K63-linked chains),
and both linkage type and chain length can act as functionally
distinct signals [63,64]. For example, it is well established
that K48-linked chains promote proteasomal degradation,
whereas both K63-linked chains and monoubiquitination
have nonproteolytic functions, which include kinase activa-
tion, DNA repair, ribosomal regulation, transcriptional modu-
lation, and protein localization and trafficking [61,63,65].
E3 ubiquitin ligases are generally categorized into two
broad classes: HECT (homologous to E6-AP carboxyl ter-
minus) domain E3s, RING (really interesting novel gene)
finger E3s [61,62,66], and its relatives, including PHD (plant
homeodomain) and U-box domain–containing proteins
[67]. The HECT domain is an approximately 350-amino-acid
Figure 2. General overview of the ubiquitin and UBL protein conjugation pathways. (1) Ubiquitin, SUMO, and NEDD8 are synthesized as precursors that are
processed at a conserved C-terminal glycine residue by the hydrolase activity of deubiquitinating, desumoylating, and deneddylating enzymes, generating an
exposed Gly–Gly motif that serves as the attachment site to target substrates. (2) The exposed C-terminal glycine of ubiquitin/SUMO/NEDD8 is adenylated by an
activating (E1) enzyme in an ATP-dependent manner and is transferred to an active E1 cysteinyl side chain through a thiol ester linkage. (3) Activated ubiquitin/
SUMO/NEDD8 is subsequently transferred to a conjugating (E2) enzyme, forming another thiol ester linkage. (4) A ligase (E3) transfers ubiquitin/SUMO/NEDD8 to
the e amino group of a substrate lysyl residue of target substrates, resulting in the formation of an isopeptide bond.
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C-terminal region that was originally identified in the cellular
protein, E6-AP (E6-associated protein) [68]. Approximately
35 amino acids upstream of the C-terminus of the HECT
domain lies an active cysteine that accepts ubiquitin from a
bound E2 forming a thiol ester intermediate, which subse-
quently transfers ubiquitin to substrates [61,65]. In contrast,
RING finger E3s are adaptor proteins, where the RING
domain serves to both recruit E2-conjugating enzymes to
the substrate and act as cofactors that enhance substrate
modification by E2 [62]. RING finger domains possess the
consensus sequence CX2CX(9–39)CX(1–3)HX(2–3)C/
HX2CX(4–48)CX2C, where the cysteines and histidines
function to coordinate zinc binding [66]. RING finger E3s
can function as single proteins or in multiprotein complexes.
The stability of all three p53 family members is regulated by
various RING and HECT E3 ligases. These E3 ligases play
important roles in regulating protein stability under normal
conditions and following a stress response.
p53 is ubiquitinated by a number of cellular E3 ubiquitin
ligases (Figure 3A). Initially, it was thought that proteasomal-
dependent regulation of p53 stability was solely determined
by the RING finger E3 ubiquitin ligase, Mdm2. Initial studies
determined that Mdm2 interacted with p53 [69]; however,
only later did studies demonstrate that Mdm2 promotes p53
ubiquitination and degradation [70–73]. Recently, Li et al.
[74] determined that, in contrast to polyubiquitination, which
promotes p53 degradation, Mdm2-mediated monoubiquiti-
nation of p53 signals its nuclear export [56]. Furthermore,
additional cofactors, including p300 and YY1, are involved in
promoting Mdm2-mediated polyubiquitination [75–77]. Addi-
tional p53-specific E3 ubiquitin ligases that target p53 for
degradation have also been described. These include two
RING finger E3 ubiquitin ligases, Pirh2 and COP1 [78,79].
Both Pirh2 and COP1 are also p53 target genes and, as a
result, participate in a negative autoregulatory feedback loop
analogous to Mdm2. More recently, Chen et al. [80] reported
the discovery of ARF binding protein 1 (ARF-BP1), a HECT
domain–containing E3 ubiquitin ligase capable of ubiquiti-
nating p53. ARF-BP1–mediated ubiquitination of p53 is
inhibited by ARF binding, providing an additional mechanism
Figure 3. Lysyl residues modified by ubiquitin and UBL proteins. The known lysines modified by ubiquitin (Ub), SUMO-1 (S1), and NEDD8 (N8) are indicated for
the p53 family. Approximate binding regions of the E2-conjugating enzymes and E3 ligases are shown. (A) Mdm2 ubiquitinates multiple p53 C-terminal lysines
(K370, K372, K373, K381, K382, and K386), as well as additional lysines located in the DNA-binding domain (K101, K120, K132, and K139) [139]. The specific
lysines ubiquitinated by Pirh2, COP1, and ARF-BP1, and the binding regions of COP1 and ARF-BP1 have not been reported. Mdm2 also promotes NEDD8 (N8)
modification of at least three C-terminal lysines (K370, K372, and K373). p53 is sumoylated at K386 by PIAS1 and PIASx. (B) PIAS1 binds all p73 isoforms, but
only TAp73a and DNp73a contain the lysine residue (627) that is sumoylated. NEDL2 and Itch bind the second C-terminal proline-rich (PY) motif; however, the
specific lysines ubiquitinated by these HECT E3 ubiquitin ligases are not known. (C) p63a is sumoylated at lysine 637. A secondary sumoylation site has been
reported at lysine 549. NEDD4 binds to the C-terminal PY motif of p63. Studies employed yeast two-hybrid screen, in vitro binding, and coimmunoprecipitation
assays, or a combination of the abovementioned techniques, to determine the binding domains shown in the figure, and specific studies are referenced in
the manuscript.
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by which ARF mediates tumor suppression. The discovery
of the abovementioned p53-specific E3 ubiquitin ligases
has greatly increased the understanding of the regulation of
both p53 stability and subcellular localization. Finally, al-
terations in p53-specific E3 ligases have been described
in cancer. Mdm2 amplification is observed in approximately
7% of human tumors [81], most commonly in sarcomas. To
date, studies have detected COP1 overexpression in breast
and ovarian adenocarcinoma tissues [82], and Pirh2 over-
expression in lung tumor samples [83]. Thus, the modulation
of p53-specific E3 ubiquitin ligase expression likely plays an
important role in tumorigenesis and in the cellular response to
chemotherapy. In contrast to p53, the regulation of p63 and
p73 stability through the ubiquitin–proteasomal pathway is
less well characterized.
Preliminary studies suggested that the ubiquitin–protea-
somal pathway regulates p73 stability. First, the proteasome
inhibitor lactascystin (LLnL) stabilized p73 protein levels [84].
Second, cotransfection experiments with exogenous ubiqui-
tin resulted in the accumulation of ubiquitinated p73 proteins
[85]. Third, in ts20 cells possessing a thermolabile E1 en-
zyme, p73 was stabilized only when the ubiquitination path-
way was inactivated [85]. Interestingly, the stability of the
proapoptotic TA isoforms and the antiapoptotic DN isoforms
of p63 and p73 appears to be differentially regulated by
ubiquitination in response to DNA-damaging agents, such
as chemotherapeutic agents. Maisse et al. [86] demonstrated
that DNp73, but not p53 and TAp73, is rapidly degraded in re-
sponse toDNA-damaging agents in a proteasomal-dependent
manner. Westfall et al. [87] also observed increased ubiq-
uitination and decreased total DNp63a protein levels in a
proteasome-dependent manner in response to ultraviolet ra-
diation and paclitaxel treatment. Thus, downregulation of the
DN isoforms of p63 and p73may result in an enhanced cellular
apoptotic response to chemotherapy treatment. However,
these studies have not identified a DNp63-specific or a
DNp73-specific E3 ubiquitin ligase.
Initial studies examining p73 stability naturally investi-
gated the E3 ligase, Mdm2. The three residues (F19, W23,
and L26) in the p53 N-terminus that directly contact Mdm2
are conserved in p63 and p73 [2,3,88,89]. As expected,Mdm2
binds to TAp73; however, in stark contrast to the known
relationship with p53, Mdm2 does not degrade p73. Instead,
Mdm2 overexpression results in p73 stabilization [90,91].
Subsequent studies aimed at understanding this differential
regulation of p53 and p73 by Mdm2 used p53–p73 chimeric
proteins and determined that amino acids 92 to 112 of p53,
which are absent in p73, contain the region responsible for
Mdm2-mediated degradation [92]. These results suggest
that this unique p53 sequence element functions as a degra-
dation signal. There are conflicting data as to whether TAp63
isoforms bind Mdm2 and whether this interaction affects
p63 stability and transcriptional activity [93–95].
Following these initial results suggesting that Mdm2 was
not an E3 ubiquitin ligase for p73, additional E3 ligases were
identified in screens for p73-interacting proteins (Figure 3B).
The first E3 ligase that was found to promote the ubiq-
uitination of p73 was NEDL2, a NEDD4-related HECT-
domain-containing E3 ubiquitin ligase [96]. The family of
NEDD4 proteins contains WW domains, which are protein–
protein interaction domains similar to SH3 domains that
mediate binding to proline-rich (PY)motifs. TheWWdomains
of NEDL2 interact with the C-terminal PY motifs of p73a and
p73b; however, NEDL2 does not bind p53, which lacks these
PY motifs. Although NEDL2 promotes p73 ubiquitination,
unexpectedly, this interaction results in stabilization and in-
creased TAp73 transcriptional activity. The exact mechanism
of NEDL2-mediated stabilization has not been determined,
and whether NEDL2 promotes specific ubiquitin-linked
chains that do not result in degradation, but rather modulate
transcription through alternative mechanisms, is unknown.
Similarly, in a search for binding partners of the PY motifs
found in the p73 C-terminus, Rossi et al. [97] identified Itch,
another NEDD4-related E3 ligase that interacts with p73
through its WW domains. Itch was shown to ubiquitinate
p73a, but not p73y or p53, that lacks PYmotifs. Itch-mediated
ubiqutination resulted in proteasomal-dependent degrada-
tion of p73 [97]. Importantly, Itch was found to degrade both
TAp73a and DNp73a isoforms. In response to DNA damage,
Itch was downregulated, potentially explaining one mecha-
nism by which TAp73 is stabilized following treatment with
DNA-damaging agents, such as chemotherapeutic agents.
However, the discovery of Itch does not explain the prefer-
ential ubiquitination and degradation of theDNp73 isoforms in
response to DNA damage. Instead, the authors suggest
that Itch plays a role in maintaining both TA and DN isoforms
at low levels under normal unstressed conditions.
Only a few published reports have revealed potential p63-
specific E3 ubiquitin ligases (Figure 3C). One mechanism of
the preferential degradation ofDNp63 isoforms in response to
genotoxic stress has been proposed to involve stratifin-
mediated nuclear export of DNp63a followed by RACK1
(receptor for protein kinase C)–mediated proteasomal deg-
radation [98]. Stratifin (14-3-3j) expression is regulated by
several p53 family proteins, and RACK1 has been shown to
be a scaffolding protein in pathways involved in limb devel-
opment. The authors demonstrate that RACK1 promotes
the ubiquitination of DNp63 and suggest that RACK1, or a
RACK1-containing complex, functions as one of the E3
ligases that may regulate the level of DNp63a in HNSCC.
RACK1 itself does not possess any consensus HECT or
RING-type domains characteristic of typical E3 ubiquitin
ligases. Because HNSCCs often overexpress DNp63a,
cisplatin-mediated downregulation ofDNp63 through RACK1
may contribute to chemosensitivity by decreasing the levels
of DNp63a available to inactivate proapoptotic p53, TAp63,
and TAp73 isoforms. Interestingly, RACK1 interacts with
p73a, inhibiting its transcriptional activity and ability to induce
apoptosis; however, RACK1 does not appear to negatively
regulate p73a stability [99]. Recent data suggest that two
additional E3 ubiquitin ligases may be involved in p63 ubiq-
uitination. The HECT domain–containing E3 ligase NEDD4
has been shown to promote the ubiquitination and degrada-
tion of DNp63a, but not DNp63b, and this modification af-
fects dorsoventral patterning in zebrafish [100]. In addition,
the HECT E3 ubiquitin ligase Itch can associate with
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and promote ubiquitin-mediated degradation of p63 [101].
Furthermore, two critical lysyl residues of p63 that are mu-
tated in the limbmalformation syndrome, SHFM, are involved
in Itch-mediated degradation of p63.
To date, there have been no reports of E3 ubiquitin ligases
that act in a negative autoregulatory feedback loop with p63
and p73, although there is evidence for such regulation for
both of these p53 family members. Studies have shown that
p63 and p73 mutants with compromised transactivation
potential are more stable than their full-length counterparts,
and that transactivation-competent TA isoforms can act
in trans to promote the turnover of either DN isoforms or
transactivation-incompetent mutants [57–59]. However, to
date, there has been no reported E3 ubiquitin ligase involved
in an autoregulatory negative feedback loop with p63 and
p73. Interestingly, cyclin G, a transcriptional target of both
p53 and p73, has been implicated in the negative regulation
of p53 and p73 stability, which is mediated by an un-
known mechanism that is both ubiquitin-independent and
proteasomal-independent [102].
A number of ubiquitin-independent mechanisms affecting
the protein stability of the p53 family through proteasomes
have been reported. Studies from Asher and Shaul [103]
have described a ubiquitin-independent proteasomal-
dependent mechanism of regulation for both p53 and p73
through NADH quinone reductase (NQO1). Studies have
demonstrated that dicumarol and other inhibitors of NQO1
induce the degradation of p53, and the majority of NQO1
associates with 20S proteasomes [104–106]. NQO1 binds
both p53 and p73 in an NADH-dependent manner, and it has
been proposed that NQO1 acts as a gatekeeper of 20S
proteasomes, protecting both proteins from proteasomal
degradation. Furthermore, a U-box domain–containing E3/
E4 ligase, UFD2a, was also recently shown to promote the
proteasomal degradation of p73a in a ubiquitin-independent
manner and, interestingly, this effect was inhibited by cis-
platin treatment [107]. In summary, there is evidence that
p73 is regulated by the proteasome through both ubiquitin-
dependent and ubiquitin-independent pathways. Several E3
ubiquitin ligases interact with p73, but only a subset has been
shown to induce ubiquitination and degradation in vivo; to
date, these ligases do not clearly discriminate between the
TA and DN isoforms. Nevertheless, ubiquitin-mediated regu-
lation of the stability and activity of the various ‘‘tumor-
suppressor-like’’ TA and ‘‘oncogenic’’ DN isoforms of p63
and p73 may play a role in cancer development and in re-
sponse to chemotherapy.
Sumoylation of the p53 Family
The SUMO (small UBL modifier) family consists of the three
paralogues: SUMO-1 (also known as Smt3c, PIC1, GMP1,
Sentrin, and UBL1), SUMO-2 (also known as Smt3a and
Sentrin3), and SUMO-3 (also known as Smt3b and Sentrin2)
[108]. SUMO-1 is a 101-amino-acid protein that is 18%
identical and 48% homologous to human ubiquitin [109].
Processed SUMO-2 and SUMO-3 differ only by three N-
terminal amino acids and are approximately 50% identical
to SUMO-1 [110]. The SUMO conjugation pathway involves
the concerted actions of SUMO E1-activating enzymes
(SAE1/SAE2, also known as Aos1 and Uba2 in yeast), E2-
transferring enzyme (Ubc9), and E3 ligases (as summarized
in Figure 2), which include the PIAS (protein inhibitor of
activated STAT) family of RING finger proteins (siz family
in Saccharomyces cerevisiae) (reviewed in Hay [108]). One
of the interesting features of the SUMO-specific Ubc9-
conjugating (E2) enzyme is that it can directly modify sub-
strate proteins in the absence of E3 [111]. In most cases,
SUMO modification occurs within the SUMO modification
consensus motif, cKxE (where c is a hydrophobic acid and
x is any residue) [112]. Sumoylation has been reported
to have diverse functional effects involved in the regulation
of subcellular transport, transcriptional activity, chromosome
segregation, and cell cycle control [108]. All three p53 family
members are regulated by SUMO-1 modification, affecting
their stability, transcriptional activity, and ability to induce cell
cycle arrest and apoptosis.
The first indication that p53 was a target of SUMO-1
conjugation came from a report that human Ubc9 associates
with p53 in yeast [113]. Subsequently, Gostissa et al. [114]
discovered SUMO-1 as a p53-interacting protein in a yeast
two-hybrid screen, and Rodriguez et al. [115] investigated
SUMO-1 modification as a mechanism of p53 stabilization in
response to genotoxic stress. Both studies demonstrated that
p53 is covalently modified by SUMO-1 in the C-terminus
(K386) and that sumoylation results in increased p53 tran-
scriptional activity (Figure 3A). In support, Muller et al. [116]
reported that the p53 mutant (K386R) that is defective for
SUMO-1 conjugation had slightly impaired apoptotic activity.
However, since the initial publications describing p53 sumo-
ylation, there have been conflicting reports as to the func-
tional effects of this p53 modification (reviewed in Melchior
and Hengst [117]). Three members of the PIAS family of E3
SUMO ligases (PIAS1, PIASxb, and PIASy) were later found
to interact with p53, and both PIAS1 and PIASxb were
reported to promote sumoylation of p53 [118–121]. The role
of the different PIAS proteins has also been controversial.
Schmidt and Muller [121] reported that both PIAS1 and
PIASxb strongly repressed the transcriptional activity of
p53, and Megidish et al. [119] reported that PIAS1 is an
activator of p53 transcription that stimulates p53-dependent
G1 arrest of the cell cycle. Interestingly, both studies reveal
that PIAS-mediated effects were independent of its sumo-
ylation function. In addition, PIASy was reported to inhibit p53
transcriptional activity, but not its ability to induce apoptosis
[120]. The difficulty in the elucidation of the function of
sumoylation may be explained by the limitations of the
techniques employed and, more importantly, by the fact that
a number of regulators of p53 function, such as Mdm2,
MdmX, ARF, and PML, are also regulated directly by
SUMO-1 conjugation and the PIAS family, or play a direct
role in p53 sumoylation [122–126].
Like p53, both p63 and p73 are sumoylated. Minty et al.
[127] demonstrated that the C-terminus of p73a associates
with Ubc9, and that SUMO-1 covalently modifies both TA
and DN isoforms of p73a at K627 (Figure 3B). The shorter
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C-terminal isoform p73b does not associate with Ubc9 and
lacks the p73a lysine that is sumoylated. The authors
reported that sumoylation of p73a does not affect its tran-
scriptional activity, but instead alters its subcellular localiza-
tion and promotes degradation [127]. Subsequently, PIAS1
was found to bind p73 in a region that includes theODdomain
and, therefore, is able to interact with all p73 isoforms in the
nucleus [128]. PIAS1 can only sumoylate the a isoforms of
p73, and sumoylated p73 is located exclusively in the nuclear
matrix. PIAS1 was also shown to stabilize p73a, but this
stabilization was, in fact, independent of its sumoylation
function. PIAS1 also inhibited TAp73a transcriptional activity,
and this effect was dependent on the sumoylation function of
PIAS1. The authors suggest that the C-terminal TAp73b
isoform may have higher basal transcriptional activity due
to the fact that it is not a substrate of SUMO-1, and that PIAS1
acts as a checkpoint regulator of G1 and G2 exit by negatively
regulating TAp73a-mediated transcription of p21 through
sumoylation. Further studies are necessary to elucidate
whether sumoylation and/or PIAS binding plays a role in
modulating the activity of TA or DNp73 isoforms in cancer.
Sumoylation of p63 is also thought to play an important
role in regulating its biologic activity, and dysregulation of p63
sumoylation may represent an underlying mechanism of
human developmental disorders associated with p63 muta-
tions. Similar to p73, Ubc9 associates with the C-terminal
domain of p63a and catalyzes SUMO-1 conjugation at K637,
with K549 serving as a potential secondary sumoylation site
[129,130] (Figure 3C). Another commonality between the
sumoylation of p63 and the sumoylation of p73 is that it
appears that sumoylation destabilizes p63a protein levels
[100,129]. Studies have also reported that sumoylation mod-
ulates the transactivation activity of both TA and DN isoforms
of p63. Sumoylation-defective TAp63a and DNp63amutants
have dramatically increased transcriptional activity [129,130].
However, TAp63a sumoylation-defective mutants mediate
both the upregulation and the downregulation of different
subsets of critical genes involved in cell differentiation
and limb morphogenesis [130]. For example, sumoylation-
defective mutants are unable to regulate target genes impli-
cated in bone and tooth development, such as RUNX, and
thus may contribute to the pathogenesis of SHFM and other
p63–EEC–like syndromes. Furthermore, it has been re-
ported that naturally occurring p63mutations found in human
developmental disorders, including SHFM, EEC, and LMS,
have altered sumoyation status [100,129,130]. This appears
to be attributed to the abrogation of Ubc9 binding and to the
loss of all or part of the SUMO-1 modification site. Therefore,
it has been proposed that sumoylation plays an important role
in regulating p63 biologic activity and is an essential step in
normal development. Whether sumoylation likewise affects
the stability or activity of p63 isoforms in tumors is not known.
There have been no reports of a p63-specific SUMO E3
ligase; however, the nucleoporin RanBP2 has been shown
to associate with DNp63a [130]. Lastly, it is still not clear what
effects SUMO-2 and SUMO-3 may have on the p53 family,
and whether they have regulatory functions different from
those of SUMO-1.
Neddylation of the p53 Family
NEDD8 (Rub1 in S. cerevisiae) is an 81-amino-acid polypep-
tide that shares 57% amino acid identity with ubiquitin. The
NEDD8 conjugation pathway is composed of NEDD8 E1-
activating enzyme (APP-BP1/Uba3), E2-conjugating enzyme
(Ubc12), and E3 ligases (as summarized in Figure 2)
(reviewed inPan et al. [131]). An essential role for neddylation
in cell cycle control and embryogenesis has been demon-
strated by a variety of genetic model systems (i.e., fission
yeast, Drosophila, and mammals) [131]. Until recently, the
only known substrates of NEDD8 were the cullins—a family
of structurally related proteins that function as molecular
scaffolds responsible for the assembly of RING finger E3
ubiquitin ligase complexes. Neddylation of cullins has been
shown to enhance the ubiquitination activity of these cullin-
based RING E3s [132–134]. In 2004, two tumor-suppressor
proteins, pVHL and p53, were identified as substrates for
NEDD8 [135,136], providing further insight into the biological
role of NEDD8. These findings also raise the possibility
that other tumor-suppressor proteins are covalently modified
by NEDD8.
The first demonstration that theNEDD8pathway influences
p53 function came from a study in 2001, which demonstrated
that the mechanism of p53 degradation by the human adeno-
virus protein E4orf6 was mediated through a cullin-containing
E3 ubiquitin ligase complex consisting of Cul5, elongins B
and C, and Rbx1 [137]. Recently, NEDD8 was shown to play
a more direct role in regulating p53 activity, as both Mdm2
and p53 were found to be covalently modified by NEDD8 (Fig-
ure 3A) [136]. Using non-neddylatable p53 mutants in con-
junction with the well-characterized ts41 CHO cell line, which
possesses a thermolabileNEDD8E1enzyme, Xirodimas et al.
demonstrated that Mdm2-mediated NEDD8 conjugation of
p53 inhibits its transcriptional activity. Furthermore, NEDD8
conjugation of Mdm2, which appears to be catalyzed by an
autoneddylation process, impairs the ability of Mdm2 to inhibit
p53. In light of this finding and of the observations that the
interaction of TAp73 andMdm2 is not consistent with a role for
Mdm2-mediated ubiquitination, we investigated whether
Mdm2 promotes the neddylation of p73. We have found that
TAp73a and TAp73b, but not DNp73b, which lacks a Mdm2-
binding site, are covalently modified by NEDD8 in an Mdm2-
dependent manner (Watson and Irwin, unpublished data).
Furthermore, neddylation of TAp73b through Mdm2 inhibits
TAp73b transcriptional activity, and thismaybedue to changes
in subcellular localization (Watson and Irwin, unpublished
data). Other studies have also implicated the NEDD8 pathway
in the regulation of p73 activity, and Bernassola et al. [85]
have suggested that a cullin-containing E3 ligase regulates
p73 stability [138]. Lastly, it is not clear whether p63 is also
regulated byNEDD8modification andhow thesemodifications
may affect p63/p73 roles in tumorigenesis and development.
Conclusion and Outstanding Questions
UBL modification plays important roles in regulating the p53
family, and perturbations in these pathways have implications
for both tumorigenesis and developmental abnormalities.
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First, p53-specific E3 ligases such as Mdm2, Pirh2, and
COP1 are amplified in human cancers. Second, mutations
in p63 found in a number of developmental abnormalities
appear to affect SUMO-1–mediated regulation of p63 activity
and, potentially, p63 ubiquitination. Third, some chemother-
apeutic agents specifically mediate ubiquitination and degra-
dation of the antiapoptotic DN isoforms of p63 and p73. In
light of the accumulating evidence suggesting that the rela-
tive expression and stability of the different N-terminal iso-
forms of p63/p73 may contribute to a role in tumorigenesis,
elucidating pathways that differentially regulate the activity
and stability of TA and DN isoforms, such as through TA-
specific or DN-specific E3 ligases, may have important ther-
apeutic implications.
Many outstanding questions regarding UBL modification
and the p53 family remain. First, p63 and p73 appear to be
regulated by an autoregulatory feedback loop analogous to
the p53–Mdm2, Pirh2, and COP1 pathways; however, spe-
cific p63-inducible or p73-inducible E3 ligases have yet to be
identified. Second, pathways regulating DNp63 and DNp73
destabilization following DNA-damaging agents have yet to
be clearly elucidated. Third, in light of the recognition that
p53 exists as multiple isoforms potentially having different
functions, the question arises as to whether various p53
isoforms are differentially regulated by the p53-specific E3
ubiquitin ligases. In addition, it is still unclear whether p53
family proteins undergo multiple ubiquitin and UBL modifica-
tions simultaneously, and whether the regulation of UBL
modifications modulates other posttranslational modifica-
tions. Specifically, because acetylation occurs on lysines, it
is possible that ‘‘competition’’ for each lysyl residue could lead
to dramatically different functional outcomes. Finally, be-
cause proteasome inhibitors are being developed as thera-
peutic agents in cancer, understanding the regulatory
pathway involving ubiquitination, sumoylation, and neddyla-
tion of the p53 family that is involved in tumorigenesis and
chemosensitivity is critical to predicting the tumor types that
may respond to such therapy.
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